阿法依伯汀生物类似药(Cj)(Epoetin alfa biosimilar(Cj)) - 药物靶点：EPO receptor_在研适应症：贫血_专利_临床

概要

基本信息

药物类型

生物类似药、集落刺激因子

别名

Epokine

靶点

EPO receptor

作用机制

EPO receptor激动剂(促红细胞生成素受体激动剂)

治疗领域

血液及淋巴系统疾病

在研适应症

贫血

非在研适应症-

原研机构

CJ CheilJedang Corp.

在研机构

CJ CheilJedang Corp.

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 9003

当前序列信息引自: *****

关联

100 项与阿法依伯汀生物类似药(Cj) 相关的临床结果

登录后查看更多信息

100 项与阿法依伯汀生物类似药(Cj) 相关的转化医学

登录后查看更多信息

100 项与阿法依伯汀生物类似药(Cj) 相关的专利（医药）

登录后查看更多信息

1

项与阿法依伯汀生物类似药(Cj) 相关的文献（医药）

2003-08-01·Diabetic Medicine2区 · 医学

Therapeutic effect of recombinant human erythropoietin on anaemia with erythropoietin deficiency in diabetic patients

2区 · 医学

Article

作者: K. R. Kim ; B. S. Cha ; Y. M. Kim ; D. J. Kim ; J. S. Hahn ; K. B. Huh ; Y. S. Yun ; H. C. Lee ; C. W. Ahn ; S. K. Lim ; Y. D. Song

AbstractAims The aim of this study was to investigate the therapeutic effect of recombinant human erythropoietin (rHuEpo) on anaemia with erythropoietin deficiency in diabetic patients.Methods Twenty diabetic patients with anaemia and Epo deficiency were enrolled. All patients were treated with rHuEpo (Epokine®; 4000 U/day s.c., three times a week) for 8 weeks.Results The responder group (n = 14) had significant increments in haemoglobin compared with the non‐responder group (n = 6) (P < 0.05). No significant differences were found between the responder and non‐responder groups in terms of duration of diabetes mellitus, serum creatinine level, 24‐h urine albumin excretion rates, frequency of diabetic microangiopathy, or HbA1c. There was no difference between the two groups in terms of serum iron and total iron‐binding capacity (TIBC). Serum ferritin level was significantly higher in the responder group than in the non‐responder group (240.3 ± 108.4, 25.8 ± 3.0 µg/l, P < 0.05), as was transferrin saturation (32.7 ± 7.9%, 21.2 ± 5.3%, P < 0.05).Conclusions rHuEpo could be useful in the treatment of anaemia with erythropoietin deficiency in diabetic patients, and the degree of iron storage and functional iron deficiency might be the main cause of hyporesponsiveness to rHuEpo.

100 项与阿法依伯汀生物类似药(Cj) 相关的药物交易

登录后查看更多信息